News & Events about Kezar Life Sciences Inc.
Kezar Life Sciences, Inc. (NASDAQ:KZR Get Rating) was the target of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,600,000 shares, a decline of 7.3% from the October 31st total of 7,120,000 shares. Based on an average ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrologys (ASN) Kidney Week 2022...
Thinking about buying stock in Autohome, Bed Bath & Beyond, Kezar Life Sciences, General Electric, or Delta Air Lines? Thinking about buying stock in Autohome, Bed Bath & Beyond, Kezar Life Sciences, General Electric, or Delta Air Lines? PR Newswire NEW YORK, June 29, 2022 NEW YORK...
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: Kezar Life Sciences (NASDAQ: KZR), Nova Mentis Life Sciences (OTC: NMLSF), Agile Therapeutics (NASDAQ: AGRX), and ...